1. Home
  2. SQFTP vs CADL Comparison

SQFTP vs CADL Comparison

Compare SQFTP & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SQFTP

Presidio Property Trust Inc.

N/A

Current Price

$6.77

Market Cap

0.0

Sector

Real Estate

ML Signal

N/A

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$11.33

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SQFTP
CADL
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
1.0B
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
SQFTP
CADL
Price
$6.77
$11.33
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$19.00
AVG Volume (30 Days)
4.5K
1.2M
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
$16,814,708.00
$125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.65
$4.35
52 Week High
$15.99
$14.00

Technical Indicators

Market Signals
Indicator
SQFTP
CADL
Relative Strength Index (RSI) 51.71 42.84
Support Level $6.30 $4.91
Resistance Level $7.20 $11.36
Average True Range (ATR) 0.30 0.69
MACD -0.04 -0.26
Stochastic Oscillator 19.48 5.54

Price Performance

Historical Comparison
SQFTP
CADL

About SQFTP Presidio Property Trust Inc.

Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: